华泰证券 孔垂岩；德邦证券 刘闯；中信建投 刘慧彬；华安证券 谭 参与单位名 称及人员 姓名 国超；东北证券 方心宇；徐星投资 毛丽丽；工银安盛 劳亭嘉等 157 位参会人员 时 间 2022 年 10 月 25 日 15:30-16:30 地 点 电话方式 董事、总经理沙树壮先生，副总经理、董事会秘书陆美娇女士，副 上市公司接 待人员姓名 总经理杨兴先生 投资者关系活动主要内容 一、公司介绍 2022 年三季度经营情况 2022 年第三季度，公司实现营业总收入 1.1 亿元左右，较去年同期增长 9.79%，实现归属于上市公司股东的净利润达到 5,126.89 万元，同比增长 13.04%。 2022 年前三季度，公司实现营业总收入 34,128.01 万元，较去年同期增长 13.37%， 实现归属于上市公司股东的净利润达到 15,535.3 万元，同比增长 22.86%。产品方面， 报告期内，公司两款产品钙硅生物陶瓷骨修复材料和乳房补片，均完成首例受试者 随机入组，正式进入临床试验。在 2022 年 10 月上旬，公司产品活性生物骨取得国 家药品监督管理局下发的《中华人民共和国医疗器械注册证》。 二、问答方 ...

烟台正海生物科技股份有限公司 2022 年第三季度报告 证券代码：300653 证券简称：正海生物 公告编号：2022-047 烟台正海生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 烟台正海生物科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益 项目的情况说明 其他原因 | | | 上年同期 | | 本报告 期比上 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2022005 | --- | --- | --- | --- | --- | |---------------------------|-------|----------------------------------------------|--------------------------------------------------------------------------|-------------------------------------| | | | | | | | | | | | | | | | □特定对象调研 □媒体采访 | | □分析师会议 | | 投资者关系 活动类别 | | | □新闻发布会 □业绩说明会 □路演活动 | | | | | | □现场参观 √其他 电话会 | | | 参与单位名 称及人员 姓名 | | 交银施罗德 金 谢杰；新华基金 | 朱亦宁；嘉实基金 程佳；创金合信 赵东宇；华夏久盈 桑永亮等 | 皮劲松；汇添富基 180 位参会人员 | | 时 间 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2022006 | --- | --- | --- | --- | --- | --- | |-----------------------|------------|--------------------------------------------------------------------------------------|-------------|--------------------------------|-------------------------------------------------------| | 投资者关系 活动类别 | | □特定对象调研 □媒体采访 \n□新闻发布会 □业绩说明会 □路演活动 \n□现场参观 √其他 电话会 | | | □分析师会议 \n | | 参与单位名 | | 华泰证券 代雯、孔垂岩；中信建投 | | | 刘慧彬；华安基金 谭国超；新 | | 称及人员 姓名 | | 华基金 赵东宇；建信养老 董治国；信达澳银 刘国丰等 | 247 ...

烟台正海生物科技股份有限公司 2022 年半年度报告全文 烟台正海生物科技股份有限公司 2022 年半年度报告 2022-033 【2022 年 8 月 19 日】 1 烟台正海生物科技股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人王涛、主管会计工作负责人赵丽及会计机构负责人(会计主管 人员)张晓宁声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、成长性风险 公司产品口腔修复膜、可吸收硬脑（脊）膜补片、骨修复材料等均属于 第三类植入性医疗器械，是公司业务收入的主要来源，上述产品近些年来均 取得了较快速的增长，公司产品的良好口碑和不断扩大的品牌影响力使其在 临床应用上获得了越来越广泛的赞誉，公司在获得市场不断肯定和深感自身 使命倍增的同时，也感受到了市场环境变化带来的压力与挑战：自 2020 年以 来，"可吸收硬脑（脊）膜补片"在已经开展带量采购的江苏、山东、福建、 河南 ...

烟台正海生物科技股份有限公司2022年第一季度报告全文 证券代码：300653 证券简称：正海生物 公告编号：2022-018 烟台正海生物科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 117,732,128.60 | 102,127,623.07 | 15.28% | | 归属于上市公司股东的净利润（元） | 55,019,970.53 | 43,99 ...

Revenue and Financial Performance - The company's operating revenue for 2021 was CNY 400,175,251.94, representing a 36.45% increase compared to CNY 293,281,582.66 in 2020[21]. - The net profit attributable to shareholders for 2021 was CNY 168,552,584.39, a 42.44% increase from CNY 118,333,984.88 in 2020[21]. - The net profit after deducting non-recurring gains and losses was CNY 160,878,004.21, up 46.35% from CNY 109,923,656.88 in 2020[21]. - The net cash flow from operating activities for 2021 was CNY 166,134,014.20, an increase of 40.28% compared to CNY 118,432,079.92 in 2020[21]. - The total assets at the end of 2021 were CNY 928,920,991.12, a 15.32% increase from CNY 805,539,145.17 at the end of 2020[21]. - The net assets attributable to shareholders at the end of 2021 were CNY 785,270,986.59, reflecting a 21.42% increase from CNY 646,718,402.20 at the end of 2020[21]. - The basic earnings per share for 2021 were CNY 1.40, a 41.41% increase from CNY 0.99 in 2020[21]. - The weighted average return on equity for 2021 was 23.62%, up from 19.16% in 2020, an increase of 4.46%[21]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 15% year-over-year[117]. - The company reported a total revenue of 1.5 billion RMB in 2021, representing a growth of 20% compared to 2020[128]. Product Development and Market Expansion - The main revenue sources for the company are the oral repair membrane and absorbable dura (spinal) membrane patches, both of which are classified as Class III implantable medical devices, showing rapid growth in recent years[6]. - The company aims to develop innovative products in the field of regenerative medicine, focusing on repairing and reconstructing human tissues[32]. - The company is focused on improving its brand influence and clinical application of its products, which have received positive feedback in the market[6]. - The company is actively pursuing market expansion strategies, targeting new regions in Southeast Asia for its product distribution[121]. - New product development includes the launch of a bioactive bone material, which is expected to capture a larger market share in the dental implant sector[122]. - The company plans to expand its product offerings in the oral and soft tissue repair fields, enhancing its competitive advantage[78]. - The company has successfully participated in volume-based procurement in five provinces, including Jiangsu and Shandong, without significant pressure on performance, although future expansions of procurement may impact growth[6]. - The company received a registration certificate for a new product, "surgical packing sponge," which is expected to contribute to revenue growth[40]. - The company is in the process of registering several new products, including Active Biological Bone and Dura Mater Patch, with the latter currently in the registration submission phase[80]. Research and Development - The development and registration of new products involve complex processes with high R&D costs and long cycles, which carry inherent uncertainties[8]. - The company's R&D investment in 2021 amounted to ¥35,179,509.47, representing 8.79% of its operating revenue, a slight decrease from 9.06% in 2020[78]. - The number of R&D personnel increased by 18.52% from 54 in 2020 to 64 in 2021, with 72.22% of them being under 30 years old[78]. - The company is actively pursuing innovation with a focus on product development, including ongoing projects for dental and orthopedic applications[48][55]. - The company has established a comprehensive intellectual property protection system, including patent applications and confidentiality agreements with core technical personnel[114]. - The company holds 61 authorized patents and 88 registered trademarks as of December 31, 2021, indicating a strong intellectual property position[62]. Governance and Compliance - The company’s financial report has been verified by the board and management, ensuring its accuracy and completeness[4]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards[121]. - The company has established a governance structure that ensures independence from its controlling shareholders, maintaining a complete and autonomous business operation[125]. - The company has implemented measures to prevent fund occupation by controlling shareholders and related parties, protecting the interests of shareholders[166]. - The company has maintained a strong commitment to social responsibility, focusing on value creation and community support since its establishment[176]. - The company has established effective communication channels with investors, including a dedicated investor hotline and email, to maintain transparency[179]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[174]. - The company has established a robust internal control system in compliance with relevant laws and regulations, ensuring effective governance and management[165]. Employee and Compensation Management - The company employed 378 staff members by the end of the reporting period, reflecting a 15% increase compared to the end of 2020[57]. - The company has a total of 10 directors and senior management members listed, with varying remuneration amounts[139]. - The company has established a comprehensive salary management system, considering market demand and individual performance[152]. - The company has a structured approach to managing investor relations, with a designated secretary responsible for communication with investors[124]. - The company emphasizes employee training across various business themes, including strategic decision-making and quality management[153]. Risk Management - The company acknowledges risks related to concentrated product offerings and external environmental changes that may affect future performance[8]. - The company faces risks related to the lengthy and complex process of new product development and registration, which involves multiple stages and significant investment[109]. - The company is subject to industry policy changes and external environmental risks, particularly regarding high-value medical consumables and the ongoing healthcare reform[111]. - The quality of implanted medical devices is critical, as any quality issues could adversely affect patient health and the company's operations[112]. - The company has established a strict supplier evaluation system to mitigate risks associated with the quality of animal tissues used in its products, although national animal epidemics could pose challenges[112]. Cash Dividend and Profit Distribution - The company plans to distribute a cash dividend of 8.80 RMB per 10 shares (including tax) to all shareholders, based on a total of 120,000,000 shares, with no bonus shares issued[8]. - The company has a stable profit distribution policy, aiming for a cash dividend of at least 20% of the distributable profit if there are no major investment plans[155]. - The company has established a differentiated cash dividend policy, with a minimum of 80% cash dividend for mature stages without major expenditures[156]. - The company distributed a cash dividend of RMB 30,000,000.00 (including tax) to shareholders, amounting to RMB 2.5 per 10 shares based on 120,000,000 shares[177]. - For the reporting period, the company distributed a cash dividend of RMB 8.80 per 10 shares, amounting to a total of RMB 105.6 million, which represents 28.09% of the distributable profit of RMB 375,969,499.75[163].

1 参加山东辖区上市公司 2021年度投资者网上集体接待日活动的公告 证券代码：300653 证券简称：正海生物 公告编号：2021-070 烟台正海生物科技股份有限公司 关于参加山东辖区上市公司 2021 年度投资者 | --- | |--------------------------------------------------------------------------| | 网上集体接待日活动的公告 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 | | 误导性陈述或重大遗漏。 | 为进一步加强与广大投资者的沟通交流，烟台正海生物科技股份有限公司 （以下简称"公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网 络有限公司联合举办的"山东辖区上市公司 2021 年度投资者网上集体接待日" 活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景·路演天下"（http://rs.p5w.net/）参与本次 活动。网上互动交流时间为：2021 年 11 月 16 日（星期二）下午 14: ...

烟台正海生物科技股份有限公司2021年第三季度报告 证券代码：300653 证券简称：正海生物 公告编号：2021-065 烟台正海生物科技股份有限公司 重要内容提示: 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3、第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 | | 本报告期 | 本报告期比上年同期增减 | 年初至报告期末 | 年初至报告期末比上年 同期增减 | | --- | --- | --- | --- | --- | | 营业收入（元） | 100,045,664.37 | 22.42% | 301,023,977.33 | 39.26% | | 归属于上市公 ...

烟台正海生物科技股份有限公司 2021 年第一季度报告全文 烟台正海生物科技股份有限公司 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王涛、主管会计工作负责人赵丽及会计机构负责人(会计主管人 员)张晓宁声明：保证季度报告中财务报表的真实、准确、完整。 2 2021 年第一季度报告 2021-034 2021 年 04 月 1 烟台正海生物科技股份有限公司 2021 年第一季度报告全文 烟台正海生物科技股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 其他原因 | | 本报告期 | 上年同期 | | 本报告期比上年同 | | --- | --- | --- | --- | --- | | | | | | 期增减 | | | | 调整前 | 调整后 | 调整后 | | 营业收入（元） | 102,127,623. ...